SCHEMBL6098655

SCHEMBL6098655

CC(C)(C)OC(=O)N1CCc2ccc3ccn(CCOc4ccccc4)c3c2CC1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 2/20 0.41
OPRD1 P41143 1/20 0.40
OPRK1 P41145 1/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HSD17B10 Q99714 1/20 0.40
ESR2 Q92731 1/20 0.40
P2RX3 P56373 1/20 0.39
NR1H2 P55055 1/20 0.39
TNK2 Q07912 1/20 0.39
GPR119 Q8TDV5 4/20 0.39
NPC1 O15118 1/20 0.38
CKS1B P61024 1/20 0.38
SKP1 P63208 1/20 0.38
SKP2 Q13309 1/20 0.38
JAK2 O60674 1/20 0.38
JAK3 P52333 1/20 0.38
PTK2 Q05397 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6096133 0.87 P2RX3 (0.41) ESR2P2RX3NR1H2GPR119NPC1
SCHEMBL6098270 0.86 ESR2 (0.44) ESR2P2RX3NR1H2GPR119NPC1
SCHEMBL6099016 0.84 HTR7 (0.40) MCL1ESR2JAK2JAK3PTK2
SCHEMBL6096847 0.82 ALDH1A1 (0.44) HPGDSMN1; SMN2HSD17B10NPC1JAK2
SCHEMBL6096616 0.80 KDM1A (0.36) OPRD1OPRK1ESR2P2RX3NR1H2
SCHEMBL6097126 0.79 MCL1 (0.43) MCL1TSHRSMN1; SMN2HSD17B10NPC1
SCHEMBL6096543 0.79 ALDH1A1 (0.45) SMN1; SMN2HSD17B10ESR2NPC1
SCHEMBL6099152 0.79 ALDH1A1 (0.47) HPGDESR2NR1H2JAK2JAK3
SCHEMBL6098296 0.78 ESR2 (0.41) SMN1; SMN2ESR2NR1H2GPR119NPC1
SCHEMBL18135536 0.74 KCNA5 (0.64)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7022694-B2 Indoles and indolines having 5-HT activity PHARMACIA & UPJOHN COMPANY (US) 2006-04-04 US disclosed
EP-1406902-B1 HEXAHYDROAZEPINO[4,5-G]INDOLES AND INDOLINES AS 5-HT RECEPTOR LIGANDS PHARMACIA & UPJOHN CO LLC (US) 2005-10-19 EP disclosed
EP-1406902-A1 HEXAHYDROAZEPINO(4,5-G)INDOLES AND INDOLINES AS 5-HT RECEPTOR LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2004-04-14 EP disclosed
US-20030060458-A1 Indoles and indolines having 5-HT activity PHARMACIA & UPJOHN COMPANY 2003-03-27 US disclosed
WO-2003006466-A1 HEXAHYDROAZEPINO (4, 5-G) INDOLES AND INDOLINES AS 5-HT RECEPTOR LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2003-01-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030060458-A1 Indoles and indolines having 5-HT activity TPH1, HTR5A, TPH2 MCL1 2096/4885OPRD1 50/4885OPRK1 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.